Table 2.
Longitudinal Remission | Durability | ||
---|---|---|---|
Feature | Non-Discretized | Discretized * | |
Days since start of UST treatment | <0.05 | <0.05 | <0.05 |
HBI at the first UST dose, categorized | <0.05 | <0.05 | 0.083 |
Years between diagnosis and start of UST | <0.05 | 0.547 | 0.077 |
Number of surgeries before UST treatment onset | <0.05 | <0.05 | 0.24 |
Number of anti-TNF episodes | <0.05 | 0.09 | <0.05 |
Number of anti-integrin episodes | <0.05 | <0.05 | <0.05 |
Age at the time of signing consent | <0.05 | <0.05 | <0.05 |
BMI at baseline | <0.05 | <0.05 | <0.05 |
Sex | 0.888 | N/A | 0.842 |
Number of comorbidities | <0.05 | <0.05 | 0.296 |
Perianal disease | <0.05 | <0.05 | 0.541 |
Location of CD | <0.05 | <0.05 | 0.137 |
Patient ever had EIMs | 0.806 | N/A | 0.648 |
Family history of CD | 0.958 | N/A | 0.998 |
Upper gastrointestinal tract (L4) involved | 0.999 | N/A | 0.828 |
Baseline albumin | <0.05 | 0.431 | 0.357 |
Baseline fecal calprotectin | <0.05 | 0.26 | <0.05 |
Baseline hemoglobin | <0.05 | 0.77 | <0.05 |
Baseline CRP | <0.05 | <0.05 | <0.05 |
Under Steroids at first UST dose | <0.05 | <0.05 | 0.237 |
Under Immunosuppressants at first UST dose | <0.05 | <0.05 | 0.813 |
Number of concomitant Steroid courses | <0.05 | <0.05 | <0.05 |
Variables that were significant in longitudinal remission (non-discretized) and durability models are indicated in bold. * All features discretized, except for “days since start of UST treatment”. BMI, Body Mass Index; CD, Crohn’s Disease; CRP, C-reactive protein; EIM, extraintestinal manifestation; HBI, Harvey Bradshaw Index; TNF, Tumor Necrosis Factor; UST, ustekinumab.